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Development and implementation of take-home naloxone kit for patients admitted to
the emergency department of a large tertiary care hospital

Health & Services

Myung Seon (Amy) Song, PharmD; Pamela Levine, PharmD, BCPS; Katharine F. Marshall, MD; Chelsea Harmon, 2020 PharmD Candidate

Background
• In 2017, more than 70,000 people in the United
States died from drug overdose; approximately 75%
of unintentional opioid-overdose deaths occurred
outside of a medical setting.
• Naloxone is an opioid antagonist that can rapidly
reverse an opioid overdose when administered
properly.
• Cost, legal concerns, and social stigma are barriers to
naloxone access.
• Community overdose education and naloxone
distribution (OEND) programs have demonstrated
that take-home naloxone kits (THNK) increase
reversal agent access and are associated with
reduced opioid-overdose mortality rates.
• From January 2016 – June 2019, about 4,016
emergency department (ED) and urgent care visits in
the Portland tri-county area (Clackamas, Multnomah,
and Washington) were due to opioid overdose.
• The ED is a critical intervention point for providers
and pharmacists to engage patients with or at-risk of
opioid overdose and to provide evidence-based
therapy such as a take-home naloxone kit.

Purpose
• To reduce the number of opioid overdose deaths in
the community

Labs on
admission:
Objectives

Primary Objective
• To develop and implement a take-home naloxone kit
protocol in the ED of a large tertiary care hospital
Secondary Objective(s)
• To increase patient access to opioid reversal agent by
prescribing and dispensing kits
• To provide safe medication use and naloxone
administration technique education to patients,
family members, and/or friends

Discussion

Development Process
Project Timeline

•
•

•
Implementation Algorithm

•

•

Challenges
• Prolongation of protocol development due to
various factors:
• Determining the inclusion criteria
• Coordinating with various stakeholders
• Obtaining funds to purchase naloxone
• Delay in IRB approval due to group of
patients being identified as “high risk”
• Implementation of protocol postponed given the
current COVID-19 pandemic
Future Considerations
• Secure adequate funding for project prior to
development of a study/protocol
• Develop a protocol to be reviewed and approved
by Pharmacy and Therapeutics (P&T) committee
prior to IRB submission to prevent delays

Methodology
Study Design
• Retrospective quasi-experimental study, pre-post
intervention
• Pre-intervention: April 2017 – September 2019
• Post-intervention: upon IRB approval – May
2020
Inclusion Criteria
• ≥ 18 years AND either of the following:
• History of emergency medical care for
intoxication or overdose
• Identified risk of opioid overdose
• Pre-intervention: discharged with naloxone
outpatient prescription
• Post-intervention: discharged with take home
naloxone kit or prescription

Next Step
• Adaptation of parts of the study to take place in
two large tertiary care hospitals
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Exclusion Criteria
• Pregnant women

Development
A literature search was performed for evidencebased evaluation of strengths and limitations of
similar study design.
Key stakeholders were identified and engaged to
determine their interest in the study and to gain
support.
• ED physicians to identify at-risk patients and
prescribe THNK/prescription upon discharge
• ED nurses to provide education to patients,
family member(s), or friend(s) prior to
discharge
• Pharmacy informaticists and analysists to
build THNK order set
• Pharmacy department to create THNK and
store in Pyxis
Intranasal naloxone was selected as formulation
of choice based on convenient drug
administration and ease-of-use for laypeople.
Operational and cost consideration were
reviewed to purchase naloxone
• Obtained $10,000 grant from a philanthropic
arm of the hospital to support the initiative
for uninsured and/or homeless patients
THNKs to include 2 intranasal naloxone (Narcan),
a medication guide, and an educational insert.
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